All News

wonder if vit D is a surrogate for poor health, low SES, diet? In #SARSCoV2 infection low vit D has worse outcomes but clusters racially (⬇️ by skin tone) & seems related to SES. But perhaps adding vit D can help immune system & be anti-inflammatory #EULAR2021 @RheumNow POS0100 https://t.co/TEf52bLs0i

Links:

Janet Pope Janetbirdope ( View Tweet)

Deucravacitinib (TYK2i) - phase II trial for PsA ⭐️ACR20, 50, 70 response ⭐️HAQ-DI response ⭐️LEI/SPARCC response ⭐️MDA response Abs#OP0227 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

Risankizumab (IL-23i) phase III trial for PsA inadequate response to biologic ⭐️ACR20, 50,70 response ⭐️significant resolution of enthesitis/dactylitis Abs#OP0228 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

Latest GRAPPA guidelines for treatment of PsA Abs#OP0229 #EULAR2021 @RheumNow https://t.co/YlHHQsFGC8
Robert B Chao, MD doctorRBC ( View Tweet)
What can define +MRI for active spine lesions in axSpA? *⃣ BME in >/=4 vertebral corners (VCs) *⃣BME in >/= 3 VCs if w/ at least 1 non-corner inflamm lesion *⃣BME in >/=1 VC if w/ at least 2 VC fat lesions Such cut-offs achieve >/= 95% specificity OP0252. #EULAR2021 @Rheumnow https://t.co/5CTan2BgLK
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
Lower ILD incidence in PsA than RA in a large Nordic registry ⭐️ No significant ⬆️ in ILD in those using MTX Abs#OP0222 #EULAR2021 @RheumNow https://t.co/lgGhu1Hmd6
Robert B Chao, MD doctorRBC ( View Tweet)
Key points on phenotypes in PsA per Dr. Dafna Gladman: ⭐️Oligoarticular & polyarticular PsA pts have the same burden of dz ⭐️Dactylitis assoc w/ greater dz severity & US synovitis + erosive changes in DMARD-naive early PsA pts #EULAR2021 @RheumNow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Dr Dehlin presents Swedish data showing ⬆️ risk of all cause mortality (HR: 1.08 (95% CL: 1.05-1.11) and most comorbidities but a ⬇️ risk dementia in gout 0.68 (0.60-0.77) @RheumNow #EULAR2021 Abstr#OP0208 https://t.co/0ojpSbfIHM
Richard Conway RichardPAConway ( View Tweet)
#EULAR2021 Gender differences in chronic #arthritis 🙋🙋‍♂️ ▶️ POS1061: The Italian prospective SIRENA study: women do worse at the onset of #psoriaticarthritis 🇮🇹 ▶️ POS0208: The Austrian Registry BIOREG: women showed lower response rates to #TNFi 🇦🇹 > LA https://t.co/JNxrqimp2Y
ARD & RMD Open ARD_BMJ ( View Tweet)
Phenotypes in axPsA per Dr. Gladman: ⭐️15% develop axial dz at 10y: # of radiographic damaged joints, periostitis, & ⬆️ESR predictive. HLA-B27 no longer predictive ⭐️Buttock pain & IBD more common in axial dz ⭐️M had more axial dz + radiographic damage #EULAR2021. @Rheumnow

Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)

Dr Deodhar on upadacitinib in axial PsA. Appears to be effective in combined analysis of SELECT-PsA 1 and 2. @RheumNow #EULAR2021 Abstr#0233 https://t.co/fBMWVb3oBd
Richard Conway RichardPAConway ( View Tweet)
Israeli study of all cause mortality in PsA vs general population ⭐️no increased mortality in PsA group ⭐️leading causes of death was cancer in both groups ⭐️age, male sex, BMI, socioeconomic status, PsO associated with ⬆️mortality, NOT DMARDs Abs#OP0219 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

Metabolomic profiling for PsA showed vLDL, triglycerides; apolipoprotein B, glycoprotein acetylene associated with increased CV events… Do you monitor cholesterol levels in your PsA pts? Abs#OP0221 #EULAR2021 @RheumNow

Robert B Chao, MD doctorRBC ( View Tweet)

Talk about unmet need. We must get better Rx for #Sogren’s Syndrome! Large survey show quality of life v poor in SS & correlates with degree of dryness in lacrimal & salivary glands POS0102 #EULAR2021 @eular_org @RheumNow

Janet Pope Janetbirdope ( View Tweet)

If we want drugs to be effective in #Sjogren’s Syndrome we need to see activity. The #Eular SS disease activity index ~ESSDAI in 511 SS pts found >50% w moderate to severe values BUT how much is Reversible ie fibro, fatigue, scarred glands? POS0105 @RheumNow @eular_org #EULAR2021

Janet Pope Janetbirdope ( View Tweet)

Disappointed to have missed lots of interesting sessions at Day 3 #EULAR2021 but look forward to catching up, starting with the difficult-to-treat #rheumatoidarthritis session! I particularly like this helpful summary on complexities & factors to consider in patients with D2T RA. https://t.co/H8n9Q2QNDW
Mrinalini Dey DrMiniDey ( View Tweet)
Cool special effects in #EULAR2021 symposium: A practical guide to the use of JAKi in RA & SpA. Beamed in & out of talk like #StarTrek @eular_org @RheumNow https://t.co/y4qToeFKE7
Janet Pope Janetbirdope ( View Tweet)
What does this graph represent to you? To me: we have a whole lot of PsA that all work equally well.. It’s time for more personalized approach to PsA treatment! Excellent talk by @DrLauraCoates Abs#OP6937 #EULAR2021 @RheumNow https://t.co/1NKLfmH2y5
Robert B Chao, MD doctorRBC ( View Tweet)
Day 3 #EULAR2021 - A dose of #physicalactivity 🏃🏼 before conference to keep me sane with all interesting stuff presented https://t.co/jew2T9lnwB
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
Similar efficacy of PsA enthesitis treatment between adalimumab and secukinumab ⭐️mean change and resolution of enthesitis similar ⭐️resolution of equal but ⬇️ in pts with ⬆️ baseline enthesitis activity ⭐️rate of relapse ⬇️ and similar Abs#POS0194 #EULAR2021 @RheumNow https://t.co/uPE4kmotCY
Robert B Chao, MD doctorRBC ( View Tweet)
×